MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ:MLTX traded down $0.01 on Friday, hitting $41.76. 302,843 shares of the company's stock were exchanged, compared to its average volume of 439,783. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -32.37 and a beta of 1.28. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $58.26. The business's 50 day simple moving average is $46.49 and its two-hundred day simple moving average is $48.94.

Analysts Set New Price Targets

Several research firms have issued reports on MLTX. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday. The Goldman Sachs Group lowered their price target on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday. Needham & Company LLC raised their price objective on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Wedbush reaffirmed an "outperform" rating and set a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, MoonLake Immunotherapeutics currently has an average rating of "Buy" and an average price target of $83.20.

Remove Ads

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.